ValuEngine cut shares of Eyenovia (NASDAQ:EYEN) from a buy rating to a hold rating in a research note issued to investors on Thursday, ValuEngine reports.

A number of other equities research analysts have also recently issued reports on the stock. Zacks Investment Research raised shares of Eyenovia from a hold rating to a buy rating and set a $3.75 target price for the company in a research report on Friday, August 16th. HC Wainwright reduced their target price on shares of Eyenovia from $12.00 to $10.00 and set a buy rating for the company in a research report on Wednesday, October 30th.

Shares of Eyenovia stock traded down $0.08 during trading on Thursday, reaching $2.75. The company’s stock had a trading volume of 49,700 shares, compared to its average volume of 137,700. The business’s 50-day moving average price is $3.14 and its 200-day moving average price is $3.91. The firm has a market cap of $46.04 million, a PE ratio of -1.51 and a beta of 1.03. Eyenovia has a 52 week low of $2.40 and a 52 week high of $6.98.

Eyenovia (NASDAQ:EYEN) last announced its earnings results on Wednesday, November 13th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.05. On average, equities analysts forecast that Eyenovia will post -1.51 EPS for the current year.

In other news, major shareholder Stuart M. Grant acquired 29,945 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was acquired at an average price of $2.70 per share, with a total value of $80,851.50. Following the completion of the transaction, the insider now directly owns 2,226,183 shares of the company’s stock, valued at approximately $6,010,694.10. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Stuart M. Grant acquired 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The shares were purchased at an average cost of $3.14 per share, with a total value of $47,100.00. Following the transaction, the insider now directly owns 2,226,183 shares of the company’s stock, valued at $6,990,214.62. The disclosure for this purchase can be found here. Insiders have purchased 99,897 shares of company stock valued at $305,253 in the last ninety days. 43.10% of the stock is currently owned by company insiders.

A hedge fund recently raised its stake in Eyenovia stock. Uniplan Investment Counsel Inc. increased its position in shares of Eyenovia Inc (NASDAQ:EYEN) by 22.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 544,896 shares of the company’s stock after purchasing an additional 99,896 shares during the quarter. Uniplan Investment Counsel Inc. owned 3.31% of Eyenovia worth $2,343,000 at the end of the most recent reporting period. 8.80% of the stock is owned by institutional investors and hedge funds.

About Eyenovia

Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.

Recommended Story: Bid-Ask Spread

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.